Login Register Cart 0
Generic placeholder image

Current Pharmacogenomics and Personalized Medicine

Editor-in-Chief

ISSN (Print): 1875-6921
ISSN (Online): 1875-6913

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

A Real-world Pilot Observational Study of Neuropathic Pain Medications in Older Adult Patients in North India

Author(s): Upinder Kaur, Vandana Dwivedi, Alok Singh, Amit Singh, Arun Raj Pandey, Kumudini Acharya and Sankha Shubhra Chakrabarti*

Volume 19, Issue 2, 2022

Published on: 18 October, 2022

Page: [77 - 85] Pages: 9

DOI: 10.2174/1875692119666220926150315

Price: $65

Abstract

Aims: This pilot study aimed to make head-to-head comparisons of multiple classes of drugs used in the management of neuropathic pain in North Indian older adult patients presenting to the geriatric clinic of a tertiary medical institution.

Background: Chronic neuropathic pain is a condition affecting nearly one third of older adults. There is paucity of data on head-to-head comparisons of drugs used in neuropathic pain in older adults. Real world studies may be a useful tool to study diverse neuropathic pain medications in this population.

Objectives: The study objective was to measure NPRS (numeric pain rating scale), GDS (geriatric depression scale), IADL (instrumental activities of daily living), HMSE (Hindi mental state examination) scores at baseline, and 4- and 12-week follow-ups in all older adult patients receiving neuropathic pain medications.

Methods: A prospective observational study was conducted involving older adult patients ≥ 50 years of age with painful peripheral neuropathy of any etiology (n=60; mean age 63±8.4 years). The patients received either gabapentin, pregabalin, duloxetine, amitriptyline, or methyl- cobalamin complex. NPRS, GDS, IADL, and HMSE scores were measured at baseline and post-therapy.

Results: All groups except amitriptyline showed statistically significant improvement in NPRS at 4 weeks and 12 weeks compared to baseline. 30% response rate at 4 weeks was maximum for pregabalin (72%) and 50% response rate at 12 weeks was maximum for gabapentin (58%). Numerically maximum improvement in depression was seen with duloxetine. There was no statistically significant difference in the measured parameters between the drug groups across time. Mean daily dose was 172 mg (gabapentin group), 75 mg (pregabalin group) and 20 mg (duloxetine group). The adverse drug reaction rate was 10.5%.

Conclusion: All drug groups showed beneficial effects on neuropathic pain at much lower doses than those described in the literature. The effectiveness at these low doses and the lower rates of adverse effects sets the foundation for larger studies in the future in diverse ethnic and aged populations.

Keywords: Neuropathy, older adults, pain, real world, drugs, personalized dosage, adverse reactions.

« Previous Next »
Graphical Abstract

[1]
Reid MC, Eccleston C, Pillemer K. Management of chronic pain in older adults. BMJ 2015; 350(2): h532.
[http://dx.doi.org/10.1136/bmj.h532] [PMID: 25680884]
[2]
Stompór M, Grodzicki T, Stompór T, Wordliczek J, Dubiel M, Kurowska I. Prevalence of chronic pain, particularly with neuropathic component, and its effect on overall functioning of elderly patients. Med Sci Monit 2019; 25: 2695-701.
[http://dx.doi.org/10.12659/MSM.911260] [PMID: 31018630]
[3]
Trivedi S, Pandit A, Ganguly G, Das SK. Epidemiology of peripheral neuropathy: An Indian perspective. Ann Indian Acad Neurol 2017; 20(3): 173-84.
[PMID: 28904445]
[4]
Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. Br J Clin Pharmacol 2004; 57(1): 6-14.
[http://dx.doi.org/10.1046/j.1365-2125.2003.02007.x] [PMID: 14678335]
[5]
Shenoy P, Harugeri A. Elderly patients’ participation in clinical trials. Perspect Clin Res 2015; 6(4): 184-9.
[http://dx.doi.org/10.4103/2229-3485.167099] [PMID: 26623388]
[6]
Monti S, Grosso V, Todoerti M, Caporali R. Randomized controlled trials and real-world data: Differences and similarities to untangle literature data. Rheumatology (Oxford) 2018; 57(S7): vii54-8.
[http://dx.doi.org/10.1093/rheumatology/key109] [PMID: 30289534]
[7]
Almeida OP, Almeida SA. Short versions of the geriatric depression scale: A study of their validity for the diagnosis of a major depressive episode according to ICD-10 and DSM-IV. Int J Geriatr Psychiatry 1999; 14(10): 858-65.
[http://dx.doi.org/10.1002/(SICI)1099-1166(199910)14:10<858::AID-GPS35>3.0.CO;2-8] [PMID: 10521885]
[8]
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9(3 Part 1): 179-86.
[http://dx.doi.org/10.1093/geront/9.3_Part_1.179] [PMID: 5349366]
[9]
Ganguli M, Ratcliff G, Chandra V, et al. A hindi version of the MMSE: The development of a cognitive screening instrument for a largely illiterate rural elderly population in india. Int J Geriatr Psychiatry 1995; 10(5): 367-77.
[http://dx.doi.org/10.1002/gps.930100505]
[10]
Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 2000; 356(9237): 1255-9.
[http://dx.doi.org/10.1016/S0140-6736(00)02799-9] [PMID: 11072960]
[11]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-45.
[http://dx.doi.org/10.1038/clpt.1981.154] [PMID: 7249508]
[12]
Karaiskos D, Pappa D, Tzavellas E, et al. Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study. Int J Geriatr Psychiatry 2013; 28(1): 100-5.
[http://dx.doi.org/10.1002/gps.3800] [PMID: 22431439]
[13]
Syed EU, Wasay M, Awan S. Vitamin B12 supplementation in treating major depressive disorder: A randomized controlled trial. Open Neurol J 2013; 7(1): 44-8.
[http://dx.doi.org/10.2174/1874205X01307010044] [PMID: 24339839]
[14]
Rathod R, Kale A, Joshi S. Novel insights into the effect of vitamin B12 and omega-3 fatty acids on brain function. J Biomed Sci 2016; 23(1): 17.
[http://dx.doi.org/10.1186/s12929-016-0241-8] [PMID: 26809263]
[15]
Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Libr 2017; 2020(2): CD007938.
[http://dx.doi.org/10.1002/14651858.CD007938.pub4] [PMID: 28597471]
[16]
Atkinson JH, Slater MA, Capparelli EV, et al. A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. Pain 2016; 157(7): 1499-507.
[http://dx.doi.org/10.1097/j.pain.0000000000000554] [PMID: 26963844]
[17]
Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract 2010; 11(1): 85.
[http://dx.doi.org/10.1186/1471-2296-11-85] [PMID: 21054853]
[18]
van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: A 13‐week, randomized trial. Curr Med Res Opin 2006; 22(2): 375-84.
[http://dx.doi.org/10.1185/030079906X80404] [PMID: 16466610]
[19]
United States Food and Drug Administration. FDA Access Data Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021446s035,022488s013lbl.pdf
[20]
Skljarevski V, Zhang S, Iyengar S, et al. Efficacy of duloxetine in patients with chronic pain conditions. Curr Drug Ther 2011; 6(4): 296-303.
[http://dx.doi.org/10.2174/157488511798109592] [PMID: 22876216]

Rights & Permissions Print Cite
Article Metrics
38
3
© 2024 Bentham Science Publishers | Privacy Policy